Table 2.
Characteristics of the included studies..
| Study | Year | Design | N. TOETVA patients | Outcomes |
|---|---|---|---|---|
| Chen et al. | 2021 | Retro PSM | 99 | 1–3, 5–9 |
| Lee et al. | 2023 | Retro PSM | 142 | 1, 3–6, 8, 9 |
| Anuwong et al. | 2018 | Retro PSM | 216 | 1, 2, 5–8 |
| Hong et al. | 2020 | Retro PSM | 82 | 1, 3–9 |
| Han et al. | 2020 | Retro PSM | 50 | 1, 3, 9 |
| Kasemsiri et al. | 2020 | Pro CST | 32 | 1, 2, 5, 7, 9, 10 |
| Wang et al. | 2020 | Retro PSM | 80 | 1–4, 9 |
| Liu et al. | 2021 | Retro PSM | 78 | 1–10 |
| Sun et al. | 2022 | Retro PSM | 28 | 1, 3–7, 9 |
| Nguyen et al. | 2022 | Pro CST | 60 | 1,2,6–10 |
| Li et al. | 2023 | Retro PSM | 101 | 1–9 |
| You et al. | 2021 | Retro PSM | 186 | 1, 3–9 |
| Lee et al. | 2023 | Retro PSM | 100 | 1, 3–7 |
PSM, retrospective propensity score-matched comparison; CST, prospective cross-sectional study. Outcomes: 1, operative time; 2, blood loss; 3, retrieved lymph nodes; 4, metastatic lymph nodes; 5, recurrent laryngeal nerve palsy; 6, hypoparathyroidism; 7, other complications (including mental nerve injury, surgical site infection, skin flap perforation, chyle leakage, seroma, hematoma, etc.); 8, postoperative pain; 9, postoperative hospital stay; 10, cosmetic satisfaction.